SEC Form 4 · accession 0001209191-18-051841
Arcadia Biosciences, Inc. · RKDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sarah Reiter
Officer — Chief Commercial Officer
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 7:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001469443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.63 | Sep 18, 2018 | A | 38,400 | A | Oct 30, 2018 | Sep 18, 2028 | Common Stock | 38,400 | 48,400 | D |
Explanation of responses
- F1The options will vest monthly in equal installments over a period of two years from the date of the grant, subject to the Participant's continued service.